PLRX (Pliant Therapeutics) ROCE %: -39.97% (As of Mar. 2026)


PLRX Pliant Therapeutics Inc PLRX
31 GF Score
Price $1.14
! 2 Warning Signs
View Full Analysis

What is Pliant Therapeutics ROCE %?

Pliant Therapeutics PLRX +0.44% 31 ROCE % is -39.97% as of Mar. 2026. GuruFocus rates PLRX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pliant Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -39.97%.

Pliant Therapeutics  (NAS:PLRX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pliant Therapeutics ROCE % Related Terms

Pliant Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Pliant Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pliant Therapeutics ROCE % Chart

Pliant Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -39.84 -46.14 -39.51 -48.92 -51.27

Pliant Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -65.11 -57.05 -37.88 -40.08 -39.97
PLRX
31GF Score
Pliant Therapeutics Inc PLRX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pliant Therapeutics ROCE % Calculation

Pliant Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-146.785/( ( (396.949 - 33.218) + (225.228 - 16.365) )/ 2 )
=-146.785/( (363.731+208.863)/ 2 )
=-146.785/286.297
=-51.27 %

Pliant Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-80.16/( ( (225.228 - 16.365) + (202.596 - 10.359) )/ 2 )
=-80.16/( ( 208.863 + 192.237 )/ 2 )
=-80.16/200.55
=-39.97 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -39.97% mean?
Pliant Therapeutics (PLRX) has a ROCE % of -39.97% as of Mar. 2026.
Is Pliant Therapeutics' ROCE % too high?
Pliant Therapeutics' current ROCE % is -39.97%. Overall, Pliant Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Pliant Therapeutics' ROCE % compare to RLYB and LIXT?
Pliant Therapeutics' ROCE % of -39.97% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Pliant Therapeutics's current ROCE % is -39.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pliant Therapeutics stock overvalued right now?
Pliant Therapeutics (PLRX) has a current ROCE % of -39.97%. The current ROCE % is -39.97%. Pliant Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Pliant Therapeutics (PLRX), the current ROCE % is -39.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pliant Therapeutics Business Description

Other Exchanges 9PT:Germany
Address 331 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
31GF Score

Get the complete analysis for PLRX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.14
Price